Business
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Scangos, who currently helms Vir Biotechnology, is expected to coordinate the industry’s response to the increasing coronavirus threat.
“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline,” said Daniel O’Day, Gilead’s chairman and chief executive officer.
Co-founder of Brisbane-based gut analysis company Microba, Professor Gene Tyson, will head up a new field of microbiome-focused research at the Queensland University of Technology.
Insilico Biotechnology AG announces the opening of their first subsidiary in the United States, located in Boston, MA.
The company expects to decrease its operating expenses by about 40% this year compared to 2019.
The novel coronavirus that causes the disease COVID-19 continues to spread and has now been diagnosed in more than 50 countries.
Brandicourt stepped down from his role as chief executive officer of Sanofi last year.
The company offered 12 million shares at $18 per share and raised $216 million, 72% more than originally expected.
Biogen and Sangamo Therapeutics announced a broad global licensing collaboration deal to develop and commercialize several compounds for a range of neurological and neuromuscular diseases.
Biopharma and life sciences strengthen their executive leadership teams and boards with this week’s Movers & Shakers.